Date: 07-Sep-2020

BeiGene Announces Inclusion Of Its Shares In The Shanghai-Hong Kong And Shenzhen-Hong Kong Stock Connect Programs

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BeiGene Co.,Ltd (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the company’s ordinary shares, which trade on the Hong Kong Stock Exchange, will be included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective on September 7, 2020. In addition, BeiGene’s ordinary shares will be included in Hang Seng Composite Index (HSCI).

“We are excited to be included in the Stock Connect programs and the HSCI, as one of the first biotech companies listed in Hong Kong and the first biotech company with dual primary listings on NASDAQ and the Hong Kong Stock Exchange,” commented John V. Oyler, Chairman, Co-Founder and Chief Executive Officer of BeiGene. “We expect that the inclusion in the Stock Connects and the HSCI can allow us to access a broader investor base in mainland China.”The Stock Connect programs are a unique collaboration between the Hong Kong, Shanghai and Shenzhen stock exchanges. The Stock Connects allow international and mainland Chinese investors to trade securities in each other's markets through the trading and clearing facilities of the participating exchanges. The Stock Connects established a two-way trading link between stock exchanges in mainland China and Hong Kong. The Stock Connects allow qualified mainland China investors to access eligible Hong Kong shares (Southbound) as well as Hong Kong and overseas investors to trade eligible A shares (Northbound), subject to